• Hemostemix appointed Prof. Dr. Ernst von Schwarz as principal investigator for its VesCell (ACP-01) longevity clinical trial.
• Von Schwarz has three decades in cardiovascular and regenerative medicine; triple board certified transplant surgeon, cardiologist, physician-scientist at Cedars-Sinai, UCLA.
• He has published 150+ papers; co-authored Hemostemix’ retrospective VesCell transcatheter implantation study in ischemic, non-ischemic cardiomyopathy patients.
• Trial targets longevity markers tied to health-span, including cardiovascular function, six-minute walk performance, cognition, inflammation-linked immune measures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemostemix Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608120823NEWSFILECNPR____20260812_309315_1) on August 12, 2026, and is solely responsible for the information contained therein.